Ionis Pharmaceuticals (IONS) EVP Baroldi Buys $277K of Stock
Ionis Pharmaceuticals EVP Joseph Baroldi bought 5,635 shares valued at $277,181.14.
Reviewed by automated data checks against the source filing. How we make and check alerts
Joseph Baroldi, EVP, Chief Business Officer at Ionis Pharmaceuticals, Inc. ($IONS), bought 5,635 shares at an average price of $49.19, worth about $277,181.14, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IONS is up 2.5% after 1 week, down 31.1% after 1 month and down 47.1% to date (from the $81.18 close on Jun 26, 2026).
IONS
Ionis Pharmaceuticals, Inc.
Key Points
- Joseph Baroldi, EVP at Ionis Pharmaceuticals, bought 5,635 shares worth $277,181.14 on June 26.
- Ionis Pharmaceuticals, trading near $80.69, has a market cap of about $13.4 billion and a 52-week high of $86.74.
- Analyst firms like Leerink Partners and HC Wainwright maintain a 'buy' rating with targets up to $130.
Get $IONS trade alerts by text
We text you when insiders, Congress or big funds trade $IONS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Ionis Pharmaceuticals, Inc. alert may contain errors. Disclosures
Joseph Baroldi, Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), made a significant purchase of company shares. On June 26, Baroldi bought 5,635 shares at an average price of $49.19, totaling approximately $277,181. This transaction was not part of a 10b5-1 trading plan.
Insider Buying and Selling at Ionis Pharmaceuticals, Inc.
In addition to Joseph Baroldi's purchase, several other insider transactions took place on June 26. Eugene Schneider, EVP and Chief Clinical Development Officer, bought 26,000 shares at $60.89 and sold an equivalent amount at $81.05 under a planned sale. Patrick O'Neil, EVP CLO & General Counsel, sold 3,069 shares at $80.00, also under a planned sale.
Ionis Pharmaceuticals, Inc. Stock Up 78.4%
Shares of Ionis Pharmaceuticals traded near $80.69 on Wednesday. The company, with a market cap of about $13.4 billion, operates in the biotechnology sector. It has a 52-week low of $39.37 and a high of $86.74, with a 50-day moving average of $75.05. Ionis has a current ratio of 4.10 and a quick ratio of 2.86, but its forward P/E ratio isn't meaningful due to negative earnings.
Analysts Set New Price Targets
Analysts have been active in setting new price targets for Ionis Pharmaceuticals. On June 25, Goldman Sachs maintained a 'hold' rating with a price target of $75. Leerink Partners and HC Wainwright & Co. both maintained 'buy' ratings, with price targets of $129 and $130, respectively. The consensus recommendation remains a 'buy', with a mean target price of $105.91 based on 23 analyst opinions.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California. It focuses on developing RNA-targeted medicines for various diseases. The company offers treatments for conditions like spinal muscular atrophy, hereditary angioedema, and amyloidosis. It also has a robust pipeline of products in clinical trials and strategic collaborations with major pharmaceutical firms like Biogen, GSK, and AstraZeneca. Ionis was founded in 1989 and is led by CEO Dr. Brett P. Monia.
Bottom Line
The purchase by Joseph Baroldi underscores insider confidence in Ionis Pharmaceuticals' prospects. Investors often monitor insider transactions as potential indicators of a company's future performance. However, it's important to remember that such filings reflect past transactions and may not indicate current positions or future intentions.
Related Filing Alerts
Source: Joseph Baroldi's Form 4 filing on $IONS (Jun 26, 2026). Find the original filing: IONS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts